Drug Profile
Nitric oxide synthase gene therapy - Trizell/Valentis
Latest Information Update: 31 May 2007
Price :
$50
*
At a glance
- Originator Ark Therapeutics; Valentis
- Developer Valentis
- Class Cell therapies; Gene therapies
- Mechanism of Action Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Vascular restenosis
Most Recent Events
- 31 May 2007 Discontinued - Preclinical for Vascular restenosis in USA (Injection)
- 07 Jan 2004 No development reported - Preclinical for Vascular restenosis in USA (Injection)
- 07 Feb 2001 Eurogene is now called Ark Therapeutics